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Abstract  
 
The negative symptoms of psychosis and depressive symptomatology share several features e.g. low 
motivation, apathy and reduced activity. Understanding the associations between these two sets of 
symptoms will support improved assessment and the development of interventions targeting these 
difficulties in people with psychosis. This is the first large systematic review and meta-analysis to 
quantify the relationship between these two categories of symptoms, as measured in studies to date. 
PsycInfo, Embase and Medline were systematically searched to identify eligible studies. Inclusion criteria 
ensured the studies measured both depression and negative symptoms using validated measures in a 
sample of over 8000 participants with non-affective psychosis diagnoses. The search led to 2020 records 
being screened and 56 included in the meta-analysis and review. Both meta-analyses and meta-
regressions were conducted to explore the main effect and potential moderating variables. A clear 
pattern emerges showing that higher ratings of negative symptoms are associated with higher levels of 
depressive symptoms, with a small effect (Standardised Effect Size = 0.19, p<.05). This did not vary 
greatly with the measures used (SES = .19 to .26) and was not moderated by demographic variables or 
quality ratings. Interestingly, higher depressive symptoms predict a significant relationship with co-
occurring negative symptoms. However, higher negative symptoms predict that it is less likely there will 
be a relationship with co-occurring depressive symptoms. Heterogeneity was high across these analyses. 
The findings support the adoption of a symptom-specific approach to understanding the interplay 
between negative and depressive symptoms in psychosis, to improve assessment and intervention. 
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Introduction  
The negative symptoms of psychosis include low motivation, anhedonia, alogia, social withdrawal and 
blunted affect 1. Research has shown that these symptoms have a significant impact on functioning 2-4, 
with some studies suggesting these difficulties are a bigger barrier to recovery than other symptom 
domains 5, 6. Negative symptoms were initially conceptualised as primary, a core feature of 
schizophrenia-spectrum diagnoses, or secondary – present due to other factors such as substance 
misuse, medication side-effects, depression or as a response to the positive symptoms 7. This 
conceptualisation allows for the co-occurrence of depressive and negative symptoms in non-affective 
psychosis. Recent research has focused on a further distinction within negative symptoms – experiential 
vs. expressive 8 which enables more reliable measurement. Experiential symptoms include low 
motivation, anhedonia and withdrawal whereas expressive symptoms are identified as blunted affect 
and alogia. Depression also includes a range of symptoms with similarities to experiential negative 
symptoms, with loss of pleasure (anhedonia), low motivation and low mood highlighted as key in the 
diagnostic criteria 9. A narrative review concluded that depressive symptoms are very common in people 
with a schizophrenia diagnosis and worsen their prognosis; it has been reported that up to 50% would 
also meet criteria for depression 10, 11.  
 
The diagnostic conceptualisation of negative and depressive symptoms is that they relate to 
distinct disorders which are driven by different organic processes and commonly occur 12. It is important 
to consider that depression is defined by self-report criteria (experiential), whereas psychosis is defined 
by clinican-rated (expressive) criteria. Some attempt has also been made to identify people for whom 
low mood is a significant problem alongside psychosis and this has resulted in diagnoses such as 
“schizoaffective disorder”, “depression with psychotic features” and applies of course to bipolar 
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disorder. The usefulness of these diagnostic labels in clinical practice, particularly schizoaffective 
disorder, is still debated in the field 11. The DSM-V 9 recommends the assessment of eight domains in 
schizophrenia-spectrum disorders, including depression, which represents a move towards dimensional 
as well as categorical assessment. Kirschner, Aleman, Kaiser 13 concluded in their narrative review that 
the presence of depressive symptoms in someone with psychosis may be missed because of the lack of 
clarity regarding how to assess them reliably and this may negatively impact on their treatment options. 
A more recent review of the field highlights the continuing lack of clarity regarding how to validly 
distinguish whether reported phenomenology are reflective of psychotic or depressive disorder 14.  
 
The symptom-specific conceptualisation views depressive symptoms as part of the maintenance 
cycle of negative symptoms, driven by psychological processes such as low self-efficacy beliefs and 
reduced anticipatory pleasure (see Sarkar, Hillner, Velligan 15). Indeed, psychological models of psychosis 
(e.g. Garety, Kuipers, Fowler, Freeman, Bebbington 16) have proposed a direct route from emotional 
changes to psychotic symptoms.  The phenomenological overlap between negative and depressive 
symptomatology is more apparent with experiential negative symptoms which include low motivation 
and anhedonia, commonly seen in depression 9. Older measures of negative symptoms are in an 
interview format and conceptualise negative symptoms as a single construct including multiple 
symptoms, they do not make the distinction between experiential and expressive negative symptoms. 
Newer measures of negative symptoms include specific subscales of experiential symptoms and there is 
some evidence that they show good divergent validity from depressive measures 17, 18. This has been 
achieved by focusing on low motivation across several areas of functioning (social, employment, 
hobbies) rather than using terms such as “low energy” or “low mood” which can measure affective and 
somatic depressive symptoms. Experiential subscales do not assess cognitive symptoms, specifically 
beliefs about self, world and the future, and there is some indication in the literature that this may be 
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where distinctions can also be drawn from depressive symptoms although findings are mixed 19. 
Cognitions which seem to be more specific to depression are those related to guilt, hopelessness and 
suicidality. Some cognitions such as defeatist beliefs appear to play a role in negative symptoms and 
have been incorporated into the cognitive model of negative symptoms developed by Grant & Beck 20. 
There is a clear need to investigate relationships between cognitive, somatic-affective and behavioural 
phenomena associated with depressive and negative symptoms to improve targeted treatments.   
 
The evidence regarding the overlap between these symptoms has been mixed with some 
studies finding an association between depressive symptoms and negative symptoms and others 
reporting none 21-24. Studies focusing on the primary and secondary conceptualisation of negative 
symptoms consistently report low levels of co-occurring depressive symptoms in people with psychosis 
identified as having primary negative symptoms 19. The variation in findings may also be due to the 
range of measures used to assess both depression and negative symptoms in people with psychosis. It 
has been shown that in depression, measures have very little overlap with one another, reflecting the 
heterogeneity of these symptoms 25. Measures aim to have high divergent validity between depressive 
and negative symptoms, adopting the diagnostic rather than symptom-specific approach. However, a 
recent review 14 showed that the domains of anhedonia, avolition and anergia may be common to both 
and used this to suggest an overlapping, dimensional model of negative, positive and depressive 
symptoms. The findings of this narrative review concluded that the symptom domains of pessimism, low 
mood and suicidal ideation may be specific to depression, while alogia and blunted affect are specific to 
negative symptoms. Hopelessness is an important factor in terms of the relationship with suicidal intent 
and attempts, this has been shown to be present in both depression and psychosis, although 
hopelessness is more commonly seen in depression 26, 27. The time is therefore ripe for a systematic 
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meta-analysis of this field which aims to establish whether there is a quantitative relationship between 
negative and depressive symptoms in psychosis.   
 
This method improves on previous systematic reviews by applying rigorous meta-analytic techniques 
and will include studies which have assessed both negative and depressive symptoms. Finally, this meta-
analysis will be the first to look at the relationships between depression measures and specific sub-
domains of negative symptoms as assessed by newer measures, which may help to improve our 
understanding of how they interact.   
 
The following research questions will be addressed in this review and meta-analysis: 
1. Is there a significant relationship between negative symptoms and depression in people 
with a diagnosis of non-affective psychosis? 
2. Does the relationship between negative and depressive symptoms vary according to the 
measures or subscales used? 
3. Is this relationship moderated by depressive or negative symptom severity? 
4. Is this relationship moderated by the diagnosis of the sample, quality of the study or 
demographic factors? 
Method  
Literature search 
PROSPERO was examined for reviews with an overlapping research question, none were 
identified. This review was then registered on the PROSPERO database (ID: CRD42017083440). Relevant 
studies were identified through the systematic search of the databases Medline, Embase and PsycINFO 
in February 2017 with no time period specified. These databases were selected to fully capture the 
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range of journals in this field. The following search terms were used as heading or keyword searches: 
(SCHIZOPHREN* OR SCHIZOAFFECT OR PSYCHOSIS OR PSYCHOTIC) AND (NEGATIVE SYMPTOMS) AND 
(DEPRESS*). The use of search terms targeting specific depressive or negative symptoms (e.g. anergia, 
alogia, motivation) were considered but not included as the focus of this review is on the whole range of 
depressive and negative symptomatology and including individual symptoms may have biased the 
sample of papers identified. A recent narrative review14 which did include individual symptoms returned 
a similar number of papers as the current review suggesting this strategy captured all relevant papers. 
 
The current review followed the flow of information as suggested by the PRISMA statement 28. Following 
the initial search, duplicate records were removed, and the inclusion and exclusion criteria were applied. 
The search was conducted by CE and any studies where inclusion was unclear were discussed with AH 
and PAG.    
 
Inclusion criteria  
Studies were included if they (i) include a sample with at least one of the non-affective psychosis 
diagnoses (ii) include a validated measure of negative symptoms in psychosis (iii) include a validated 
measure of depression in psychosis (iv) have been published in a peer-reviewed publication (v) have 
been written in English. Studies were included if the results reported a test of a direct association 
between the negative symptom measure and depression measure regardless of whether this was the 
primary outcome of the study. Validated measures of depressive and negative symptoms were 
identified organically through the literature search – if a validation paper was cited for the measure then 
it was considered eligible for inclusion. 
 
Exclusion criteria  
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Studies were excluded if they were (i) conference abstracts (ii) book chapters (iii) theoretical or 
review articles (iv) qualitative data only was presented or (v) they were single case studies or 
dissertations. Studies were also excluded if: the sample included people with a diagnosis of bipolar 
affective disorder or depression with psychotic features as low mood is primary in these diagnoses; they 
removed people who met criteria for depression from their sample as we wished to analyse the 
relationship at all levels of depressive symptoms; they only used a single item to assess depressive 
symptoms as this was not considered sufficiently robust. Studies were also excluded if insufficient 
statistical information was provided for the paper to be included in the analyses e.g. only associations 
for change scores presented or authors did not respond to request for additional data within the time 
frame of the study (k=3)17, 29, 30.  
 
Quality assessment  
 Studies were assessed using an adapted version of the Quality Assessment Tool for Quantitative 
Studies 31; see Supplementary Material for rating scale and instructions. This was included for the 
purpose of characterising the studies included, and to analyse quality as a potential moderator of our 
findings. The measure was adapted by removing sections C, D and G which were relevant for 
randomised controlled trials only. One additional item was added which assessed whether the analyses 
of negative and depressive symptoms was outlined in the design of the study or whether it was the 
result of secondary analyses. This was identified as an important quality criterion in this group of 
studies. All studies were rated by CE and a sample of 10% (k = 6) were rated by an independent assessor. 
One of these six papers had a discrepancy greater than 2 between raters which specific to the selection 
bias item. This was discussed, and a consensus reached. The ratings were shown to have excellent 
reliability (Intraclass Correlation = .94, 95% CIs = .76 - .99).  
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Data extraction and analytic procedure  
 Based on the inclusion criteria, 56 studies were considered eligible for inclusion in the final 
meta-analyses. The following data were extracted from each study by CE: sample size, age, gender, 
ethnicity, diagnosis (% schizoaffective disorder), mean scores on depression and negative symptoms 
measures, r statistic and p value for the correlation.  To ensure each study was weighted appropriately 
where multiple Pearson’s r values were presented for different subscales these were averaged to 
combine them for the main analysis, allowing all data points to be included without introducing bias 32. 
Individual subscales were reported in sub-group analyses. All scores were converted to Fisher’s z scores 
to represent the continuous nature of the data and to minimise the risk of bias associated with 
Pearson’s r 32. All analyses were conducted in Stata 33 using the metan package for meta-analyses and 
metareg for meta-regressions. We hypothesised that the true effect sizes would vary with sample 
characteristics acting as moderating variables. Therefore, random effect models were chosen for the 
meta-analyses of main effects as well as meta-regressions and subgroup analyses 34. The main analysis 
was conducted to assess the relationship between depressive and negative symptoms and included all 
the studies. Sub-group analyses were conducted to examine this relationship when different measures 
were used. Meta-regression analyses were carried out to examine whether the severity of depressive or 
negative symptoms, age, gender, ethnicity, diagnosis or quality score moderated the findings.  
 
 For all analyses, heterogeneity statistics (I2 and τ2) are reported to examine the amount of 
variance across studies. The I2 statistic was included as it has greater power to detect true heterogeneity 
when analyses only include a small number of studies. The convention is to consider an I2 statistic higher 
than 25%, 50% or 75% as representing low, moderate or high heterogeneity respectively. The τ2 statistic 
measures the between-study variance in the meta-analyses and a value >1 is suggestive of very high 
heterogeneity 35. For the reporting of the main effect, rather than the 95% confidence interval, the more 
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rigourous 95% prediction interval,  which takes into account the heterogeneity and describes the range 
of values in which 95% of effect sizes in future studies can be expected to fall 32.  
 Publication bias was assessed with the metabias package in Stata which includes Egger’s test for 
asymmetry 36 and Begg’s test 37. A funnel plot will also be produced to aid our assessment of bias. 
Egger’s test is limited in it’s ability to detect bias in random effects models as it was designed for fixed 
effects analyses. The analysis of quality ratings as a potential moderator is also a method of bias 
analysis.  
Results  
-----Figure 1 approximately here------------------------ 
Characteristics of studies  
Fifty-six papers were included in the analyses, see PRISMA flow diagram in Figure 1. The included studies 
are summarised in Table 1 below. Based on the data available, there were 8,177 unique participants in 
these studies and 66.79% were male. The mean age reported for the samples ranged from 22.3 – 59.35 
with a composite mean age of 37.16 (SD = 9.58). Two studies selected people aged over 40 years old for 
inclusion in their sample 38, 39. A further two studies did not report mean age or gender for their samples 
40, 41 and one did not report mean age 42. Only ten studies reported the ethnicity of the sample, with an 
average of 49.25% of participants identifying as belonging to a Black and Minority Ethnic (BAME) group.  
This composite ethnicity categorisation was compared to a composite category of ‘white’ for the 
purposes of the meta-analysis to maximise power. Thirty-four of the studies included in the analyses 
only included people with a diagnosis of schizophrenia. Of the 23 studies that did include people with 
schizoaffective disorder, only 10 reported the percentage of their sample that had this diagnosis, with a 
mean of 16.12%. The majority of studies (k = 48) reported findings from community samples, two 
studies included mixed inpatient and outpatient participants and three studies included people solely 
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from an inpatient setting. Three studies reported findings from participants experiencing their first or 
second episode of psychosis.  
 
 
 
 
 
 
 
---------Table 1 approximately here------------------------
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Quality Ratings of Studies  
The quality scores are listed in Table 1. Studies generally scored moderate – high for selection of the 
sample with the majority recruiting from a wide pool of participants. Studies scored lower in this area 
when they sampled from clinic, service or ward only or their recruitment procedure was not described 
clearly. Studies did not consistently report subscales for the negative symptom measures used and this 
prevented them from achieving the full score in this section. The lower scores in the analysis section 
were given to studies which did not account for multiple correlational analyses in their analysis or 
significance levels. 
 
 Measures of negative symptoms  
 
Four measures of negative symptoms were used in the studies included in the analysis; these are 
detailed in Table 1. The most commonly used assessment was the negative symptom subscale of the 
Positive and Negative Syndrome Scale (PANSS) 43 with 34 studies using this measure. The second most 
common was also an older measure of negative symptoms – the Scale for the Assessment of Negative 
Symptoms (SANS) 44 with 17 studies using this measure. These measures are the most widely used which 
reflect the historical conceptualisation of primary and secondary negative symptoms. The newer 
measures – the Clinical Assessment Interview for Negative Symptoms (CAINS) 17(k = 5) and the Brief 
Negative Symptom Scale (BNSS) 45(k=2) were used far less often in these studies. The most important 
differences in the newer measures is that they draw a distinction between expressive and experiential 
symptoms. Where these data were reported, expressive and experiential subscales from the CAINS, 
BNSS and SANS were analysed separately in the sub-group meta-analyses. Three is the minimum 
number of studies needed to conduct a robust sub-group analysis 34 and therefore the studies which 
solely used the BNSS were not analysed separately.  
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Measures of depression  
Four measures of depression were used in the sample of studies included in the analyses; these are also 
detailed in Table 1. The most commonly used measure was the Calgary Depression Scale for 
Schizophrenia (CDSS, k = 34) 46. This measure was designed specifically for use in this population and the 
scale was developed not to include items which overlap with negative symptoms and has been shown to 
reliably distinguish these two symptom clusters 47. The second most common measure was the Hamilton 
Depression Rating Scale (HDRS, k = 16) 48 which is a more general measure used in many different 
populations and includes many of the physical symptoms of depression. The other two measures used, 
the Beck Depression Inventory (BDI, k = 9) 49 and the Montgomery-Asberg Depression Rating Scale 
(MADRS, k = 5) 50, were developed initially for the assessment of people with mood disorders and 
include the full range of depressive symptoms, including cognitive features such as hopelessness and 
low self-esteem.  
 
Meta-Analysis Findings  
1. Is there a relationship between negative symptoms and depression in people with 
psychosis? 
The meta-analysis testing the relationship between negative symptoms and depression showed 
a small but significant association between increased levels of reported negative symptoms and 
depressive symptoms in people with non-affective psychosis (k = 56, pooled standardised effect 
size (SES) = 0.194, 95% confidence interval (CI)=0.141, 0.247, z = 7.20, p<.001) (See Figure 2).  
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2. Does this relationship vary according to depression or negative symptom 
measures or subscales used?  
The relationship was consistently present across the sub-group analyses looking at each 
depression and negative symptoms measure. When the most common combination– PANSS 
Neg and CDSS- was examined the effect size was also small but significant (k = 23, pooled 
ES=0.135, 95% CI= 0.055, 0.216, z = 3.29, p=.001). The expressive (k =6, pooled ES= 0.189, 95% 
CI=0.090, 0.288, z= 3.75, p<.001) and experiential (k=12, pooled ES=0.263, 95% CI= 0.185, 0.341, 
z=6.58, p<.001) subscales also had small but significant relationships with measures of 
depression which was numerically larger for experiential subscales. However, the CIs for the 
pooled ESs slightly overlap, and so it is not possible to conclude whether there is a stronger 
relationship between depressive and experiential symptoms than alogia and blunted affect. 
Heterogeneity analyses  
The full sample included in the main effect analyses showed high levels of heterogeneity 
(p<.001, I2=79.5%, τ2=0.0283) as expected given the wide range of different measures used. The 
95% prediction interval (-0.15, .54) is displayed around the main effect size in the Forest Plot 
(See Figure 2). 
In line with this, the heterogeneity was lower in the sub-groups analyses (See Supplementary 
Material for full results) and for expressive (p=.216, I2=29.3%, τ2=0.0308) and experiential 
(p=.263, I2=25.3%, τ2=0.007) subscales the heterogeneity was even lower and non-significant.  
Publication bias  
Visual inspection of the funnel plots showed publication bias to be unlikely. This was confirmed 
by the Egger’s and Begg’s tests conducted which found no evidence of publication bias in the 
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main effect analyses (Egger’s p=0.962, Begg’s p=0.772). This was consistent across the negative 
symptom (Egger’s p=0.138-0.932, Begg’s p=0.621-1.0) and depression measures used (Egger’s 
p=0.224-0.687, Begg’s p=0.419-0.917).  
3. Is this relationship moderated by depressive or negative symptom severity? 
Meta-regression analyses using the subset of the full sample that reported severity scores 
showed that the severity of depressive symptoms positively predicted a relationship with 
negative symptoms (k=51, t=2.08, p=.044). Negative symptom severity also predicted the 
association with depressive symptoms but in the opposite direction (k=43, t= -2.45, p=0.019). As 
these analyses included the whole sample the heterogeneity was high (I2res = 78.13%, 73.84%, 
τ2=.02579, .02569) and thus the results should be considered with caution. This analysis was not 
repeated by specific measure sub-groups as the overall relationship was consistent across all 
measures when analysed separately.    
4. Is this relationship moderated by the diagnosis of the sample, quality of the study 
or demographic factors? 
To investigate whether variables which differed between samples accounted for heterogeneity 
in findings meta-regression analyses were conducted for demographic data and study 
characteristics including those studies which reported this data (see Table 1). No significant 
results were found for age, gender or ethnicity (ts=0.10-0.85, ps=0.418-0.924). The proportion 
of the sample with schizoaffective disorder also did not significantly moderate the findings 
(t=0.22, p=0.829). The quality ratings for each study were also examined to assess whether they 
moderated the presence of an association between the measures, this analysis was non-
significant (t=0.51, p=0.61).  
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------------------Figure 2 approximately here---------------------------------------- 
 
Discussion  
The findings confirm that there is a relationship between negative symptoms and depressive symptoms 
in people with non-affective psychosis. In the first large meta-analysis to examine this, with data from 56 
studies and over 8,000 unique participants, and across a range of measures, a clear pattern emerges 
showing that overall there is a small, significant relationship between depressive and negative 
symptoms. The relationship was consistent across measures, so it does not appear to be the result of 
measurement artefacts. The effect size did vary with the measure used, but not greatly. There were no 
significant moderating effects of demographic or study quality variables suggesting it is robust and 
generalisable. A non-reciprocal relationship was highlighted in the findings – higher depression severity 
was linked to higher negative symptom severity but there was an inverse relationship in the other 
direction whereby higher negative symptom severity was linked to lower depression severity. All these 
findings support the hypothesis that this relationship is consistent with a symptom-specific approach 
and highlights the phenomenological overlap in the dimensions of depression and negative symptoms.  
 
These findings support the model proposed in the recent review by Krynicki, Upthegrove, 
Deakin, Barnes 14 which suggests that an overlapping, symptom-specific approach to these symptom 
categories may best represent their relationships. This approach allows the co-occurrence of specific 
symptoms in the dimensions, as suggested by the evidence. Depression may act as a driver of negative 
symptoms as proposed in cognitive models, which highlight the role of emotion in psychosis (e.g. 
Garety, Kuipers, Fowler, Freeman, Bebbington 16). This is also consistent with the secondary negative 
symptoms conceptualisation, where depression drives the presentation of negative symptoms19. Indeed, 
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the inverse reciprocal relationship found in this study supports the existence of primary negative 
symptoms which do not predict co-occurring depressive symptoms as highlighted in the work of 
Kirkpatrick and Carpenter 51, 52. A recent factor analysis concluded that a five-factor not two-factor 
solution is more appropriate within the category of negative symptoms, providing further evidence 
supporting a symptom-specific approach53.  
 
The sub-group analyses of negative symptom sub-domains and depression suggested that, as expected, 
the experiential negative symptoms have phenomenological overlap with depression, with expressive 
symptoms appearing more distinct from depression. These symptoms of low motivation, apathy and 
anhedonia are present in the majority of both the negative and depressive symptom measures used in 
the studies in this meta-analysis. However, an important difference in anhedonia in depression and 
psychosis is not commonly assessed in these measures. A recent review highlights that people with 
psychosis do not experience a reduction in their capacity to experience pleasure54 whereas this is 
commonly seen in people with depression and described as anhedonia. Unfortunately, the subscales 
reported in the depression measures included are not detailed enough to analyse this difference in our 
findings, but it should be considered in future research. Measures such as the CDSS have attempted to 
reduce phenomenological overlap by excluding experiential symptoms in their assessment of 
depression, but this may result in false negatives and could therefore lack validity. It seems from recent 
reviews of the area that suicidal ideation, pessimism and guilt are more common characteristic of 
depression 14. Expressive symptoms, with poorer verbal and emotional expression, are more uniquely 
found in people experiencing negative symptoms 14,19. 
 
Importantly, the findings were not moderated by demographic variables such as age, ethnicity 
and diagnosis suggesting the depression and negative symptom relationship is present across the 
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population of people with schizophrenia-spectrum diagnoses. The quality ratings did not moderate the 
findings, although there was a limited range of scores because of the measure used and inclusion 
criteria applied to the studies.  The lack of moderation by schizoaffective disorder is perhaps surprising 
as people with this diagnosis might be expected to report more symptoms related to mood. It therefore 
tentatively suggests that the overlap between depressive and negative symptoms is consistent across 
the diagnoses included.  
 
The findings of the meta-regressions showed a non-reciprocal relationship between negative 
and depressive symptoms. As severity of depressive symptoms increases, the more likely they are to 
demonstrate a positive association with negative symptoms. However, if a person reports more severe 
negative symptoms, the less likely they are to be related to depressive symptoms. This is a cross-
sectional finding and hypotheses regarding a directional relationship are therefore speculative at this 
stage. As negative symptom severity increases the person is more likely to experience expressive deficits 
and greater apathy or numbing of emotion. This may either limit their ability to report depressive 
symptoms or be protective against them. It is important to consider that depressive symptoms are more 
often self-reported whereas negative symptoms are always interviewer-rated. This may explain this non-
reciprocal relationship in terms of how symptoms are expressed in an interview – which may be more 
challenging for someone with severe negative symptoms. Negative symptoms may also be a less potent 
bridge to co-occurring depressive symptoms 55.  The role of depressive symptoms in driving psychosis 
has been discussed previously 15, 16 and it may be that this is a more potent route to co-occuring negative 
symptoms.  A true symptom-specific approach would explore the phenomena associated with the 
concepts of “depressive” and “negative” symptoms across a broad population. Such an approach will 
assist with determining the factors contributing to the presenting symptoms, and specifically whether 
apparent negative symptoms are primary or secondary to depressive symptoms.  
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The main analysis and some of the sub-group analyses had high heterogeneity in the included 
studies which is a limitation of including different measures in the analysis, although this did increase 
power. Only two studies were excluded due to missing data, however many studies did not report the 
sample demographics, with ethnicity data particularly lacking. Meta-analyses that consider symptoms 
are only as good as the measures of those symptoms used. Several studies did not report the measure 
total scores and so they could not be included in the meta-regressions, which limits these findings. More 
robust conclusions would have been possible with a greater number of studies in the sub-group analyses 
considering subscales of both negative (i.e. expressive and experiential) and depressive symptoms (e.g. 
behavioural, cognitive and somatic-affective symptoms). The role of positive and cognitive symptoms 
cannot be elucidated from the data available, future analyses may wish to include this data if possible to 
examine whether these difficulties play a moderating role in the relationship between depressive and 
negative symptoms. The narrow range of quality ratings provided by the scale used may have limited 
the power of the moderation analysis. Future meta-analyses addressing these questions may wish to 
include a wider range of bibliographical sources, although this may increase heterogeneity.  
 
These important findings tell us that depressive and negative symptoms can both be present in 
people with non-affective psychosis. This means both should be assessed using the most current and 
robust measures, and care should be taken to ensure the measure selected captures the full range of 
symptoms the person is experiencing. It follows that treatment for both depressive and negative 
symptoms might be indicated, although further research is required to explore whether this requires 
targeting the same or different causal mechanisms.  
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The findings highlight the importance of mood across the psychosis spectrum as proposed in 
several cognitive models of psychosis 16, 56-58. A symptom-specific approach to considering these 
difficulties in the context of fuzzy boundaries between diagnostic categories may have the greatest 
clinical utility 59.  Indeed, the findings of a recent factor-analysis suggest that negative symptoms are 
best conceptualised as five factors; blunted affect, alogia, anhedonia, avolition and asociality rather than 
the two expressive and experiential factors discussed previously 53. Thus, it seems there is increasing 
evidence that each of these symptoms is best considered as a unique entity and subsequently each can 
be expected to have a different relationship with depressive symptoms. Although the findings of the 
review suggest that depressive and negative symptoms mirror each other we are aware that there is 
phenomenological complexity behind this and research focused on gaining a deeper understanding of 
these symptoms is required. This further work is needed to develop our theoretical understanding of the 
causes and maintenance factors underlying specific symptoms in order to improve therapeutic 
outcomes. Assessment of these individual symptoms is important, as the diagnostic and conceptual lines 
we have drawn so far appear to be more complex then we anticipated. The impact of these symptoms is 
at least as, if not more significant than any other group of symptoms and they are a priority for service 
users 60.  
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